Icon Plc (NASDAQ:ICLR) had its price objective boosted by Barclays PLC from $108.00 to $120.00 in a research note issued to investors on Friday, Marketbeat reports. Barclays PLC currently has an equal weight rating on the medical research company’s stock.
Other analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Icon Plc from a hold rating to a buy rating and set a $120.00 price target for the company in a research note on Thursday, August 24th. ValuEngine upgraded shares of Icon Plc from a hold rating to a buy rating in a research note on Friday, September 1st. SunTrust Banks, Inc. upgraded shares of Icon Plc from a hold rating to a buy rating and boosted their price target for the company from $93.00 to $126.00 in a research note on Monday, July 31st. Jefferies Group LLC restated a buy rating on shares of Icon Plc in a research note on Sunday, July 30th. Finally, Credit Suisse Group restated a buy rating on shares of Icon Plc in a research note on Friday, July 28th. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. The stock has an average rating of Buy and an average price target of $120.60.
Icon Plc (NASDAQ:ICLR) traded down 1.19% on Friday, reaching $119.70. 82,603 shares of the company were exchanged. Icon Plc has a 12-month low of $73.76 and a 12-month high of $123.53. The company’s 50-day moving average price is $113.86 and its 200-day moving average price is $100.60. The stock has a market capitalization of $6.47 billion, a P/E ratio of 24.28 and a beta of 0.59.
Icon Plc (NASDAQ:ICLR) last announced its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.35 EPS for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.03. The business had revenue of $440.30 million during the quarter, compared to analyst estimates of $438.09 million. Icon Plc had a net margin of 16.37% and a return on equity of 28.42%. Icon Plc’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.19 EPS. Equities research analysts anticipate that Icon Plc will post $5.34 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Barclays PLC Boosts Icon Plc (ICLR) Price Target to $120.00” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.com-unik.info/2017/10/30/barclays-plc-boosts-icon-plc-iclr-price-target-to-120-00.html.
Hedge funds and other institutional investors have recently bought and sold shares of the company. IHT Wealth Management LLC grew its stake in shares of Icon Plc by 16.9% in the 2nd quarter. IHT Wealth Management LLC now owns 166 shares of the medical research company’s stock worth $223,000 after acquiring an additional 24 shares in the last quarter. Shine Investment Advisory Services Inc. bought a new stake in shares of Icon Plc in the 2nd quarter worth $103,000. Acrospire Investment Management LLC grew its stake in shares of Icon Plc by 20.1% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock worth $117,000 after acquiring an additional 200 shares in the last quarter. Parallel Advisors LLC grew its stake in shares of Icon Plc by 20.7% in the 2nd quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock worth $133,000 after acquiring an additional 217 shares in the last quarter. Finally, Huntington National Bank grew its stake in shares of Icon Plc by 5.0% in the 2nd quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock worth $159,000 after acquiring an additional 77 shares in the last quarter. Hedge funds and other institutional investors own 91.51% of the company’s stock.
About Icon Plc
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
What are top analysts saying about Icon Plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Icon Plc and related companies.